Quick Takeaways
- IMVT - Immunovant, Inc. has 19 insiders with reported activity on this page.
- Net insider value flow over the last year: +$346,786,943.
- Recent transaction rows are available for direct filing-level review.
- Info
- Insider Trading
- Financials
- Holders
Insider Transactions Reported by 19 Insiders of Immunovant, Inc.
- Symbol
- IMVT on Nasdaq
- Location
- Durham, NC
What Changed
- Buy value: $349,999,986; sell value: $3,213,042.
- Net share flow: +16,500,695.
Why This Matters
- This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
- Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.
Official SEC Source
Insider trading overview
Last 12 monthsNet insider flow leans to buying over the last 12 months. Net value: +$346,786,943.
Buys
$349,999,986
Shares: 16,666,666
Insiders: 1
Sells
$3,213,043
Shares: 165,971
Insiders: 9
Net
+$346,786,943
Shares: +16,500,695
Insiders: -8
| Window (months) | Buy shares | Sell shares | Buy $ | Sell $ | Net $ |
|---|---|---|---|---|---|
| 0-3 | 0 | 22,321 | $0 | $556,338 | -$556,338 |
| 3-6 | 16,666,666 | 67,006 | $349,999,986 | $1,584,287 | +$348,415,699 |
| 6-9 | 0 | 10,726 | $0 | $186,954 | -$186,954 |
| 9-12 | 0 | 65,918 | $0 | $885,465 | -$885,465 |
Immunovant, Inc. executives and other stock owners filed with the SEC include:
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Roivant Sciences Ltd. | Director, 10%+ Owner | $2,379,657,147 | +$349,999,986 | +17% | Filing P/S | 12 Dec 2025 |
| Peter Salzmann | Chief Executive Officer, Director | $17,543,264 | -$488,841 | -2.7% | Filing P/S | 16 Apr 2025 |
| Frank Torti | Director | $16,667,378 | Mixed | 01 Apr 2025 | ||
| Julia G. Butchko | Chief Development Officer | $14,251,795 | Filing P/S | 21 Aug 2024 | ||
| Mark S. Levine | Chief Legal Officer | $8,124,353 | Filing P/S | 20 Nov 2024 | ||
| William L. Macias | Chief Medical Officer | $7,454,384 | Filing P/S | 19 Feb 2025 | ||
| Eva Renee Barnett | Chief Financial Officer | $5,907,965 | -$188,274 | -3.1% | Filing P/S | 16 Apr 2025 |
| Jay S. Stout | Chief Technology Officer | $5,144,413 | -$327,738 | -6% | Filing P/S | 21 Jan 2026 |
| Melanie Gloria | Chief Operating Officer | $4,920,889 | -$388,421 | -7.3% | Filing P/S | 25 Feb 2026 |
| Michael Geffner | Chief Medical Officer | $4,147,740 | -$248,280 | -5.6% | Filing P/S | 22 Oct 2025 |
| Christopher van Tuyl | Chief Legal Officer | $3,671,913 | -$362,781 | -9% | Filing P/S | 18 Mar 2026 |
| Tiago Girao | Chief Financial Officer | $3,059,135 | Mixed | 01 May 2025 | ||
| Douglas J. Hughes | Director | $2,893,721 | -$348,665 | -11% | Filing P/S | 01 Dec 2025 |
| George Migausky V | Director | $2,739,530 | Mixed | 01 Apr 2025 | ||
| Atul Pande | Director | $2,452,106 | Mixed | 01 Apr 2025 | ||
| Andrew J. Fromkin | Director | $2,056,155 | -$517,189 | -20% | Filing P/S | 01 Dec 2025 |
| Eric Venker | Chief Executive Officer, Director | $481,200 | -$342,854 | -42% | Filing P/S | 01 Apr 2026 |
| Robert Graham Susman | Director | $367,234 | Mixed | 01 May 2025 | ||
| Jake Bauer | Director | $367,234 | Mixed | 01 May 2025 |
Top shareholders of Immunovant, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Roivant Sciences Ltd. |
13D/G
3/4/5
|
Director, 10%+ Owner |
56%
|
113,327,007
|
$2,812,776,314 | +$413,666,650 | 12 Dec 2025 | |
| FMR LLC |
13F
13D/G
|
Company |
8.4%
from 13D/G
|
16,990,754
|
$431,904,967 | — | 31 Dec 2025 | |
| Deep Track Capital, LP |
13F
13D/G
|
Company |
5.6%
from 13D/G
|
11,526,971
|
$293,015,603 | — | 31 Dec 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
3.8%
|
7,779,314
|
$197,750,162 | — | 31 Dec 2025 | |
| BlackRock, Inc. |
13F
|
Company |
3%
|
6,058,216
|
$153,999,851 | — | 31 Dec 2025 | |
| ARMISTICE CAPITAL, LLC |
13F
|
Company |
2.8%
|
5,747,155
|
$146,092,680 | — | 31 Dec 2025 | |
| BAKER BROS. ADVISORS LP |
13F
|
Company |
2.7%
|
5,457,881
|
$138,739,335 | — | 31 Dec 2025 | |
| T. Rowe Price Investment Management, Inc. |
13F
|
Company |
2.5%
|
5,060,399
|
$128,636,000 | — | 31 Dec 2025 | |
| MORGAN STANLEY |
13F
|
Company |
2.4%
|
4,846,385
|
$123,195,151 | — | 31 Dec 2025 | |
| STATE STREET CORP |
13F
|
Company |
1.9%
|
3,786,926
|
$96,263,659 | — | 31 Dec 2025 | |
| RTW INVESTMENTS, LP |
13F
|
Company |
1.6%
|
3,177,850
|
$80,780,947 | — | 31 Dec 2025 | |
| Two Seas Capital LP |
13F
|
Company |
1.4%
|
2,866,962
|
$72,878,174 | — | 31 Dec 2025 | |
| Alpine Global Management, LLC |
13F
|
Company |
1.3%
|
2,626,692
|
$66,770,511 | — | 31 Dec 2025 | |
| ADAR1 Capital Management, LLC |
13F
|
Company |
1.2%
|
2,480,968
|
$63,066,207 | — | 31 Dec 2025 | |
| Point72 Asset Management, L.P. |
13F
|
Company |
0.99%
|
2,000,000
|
$50,840,000 | — | 31 Dec 2025 | |
| PERCEPTIVE ADVISORS LLC |
13F
|
Company |
0.98%
|
1,994,890
|
$50,710,104 | — | 31 Dec 2025 | |
| Woodline Partners LP |
13F
|
Company |
0.97%
|
1,975,869
|
$50,226,590 | — | 31 Dec 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.92%
|
1,857,532
|
$47,226,549 | — | 31 Dec 2025 | |
| TCG Crossover Management, LLC |
13F
|
Company |
0.82%
|
1,660,933
|
$42,220,917 | — | 31 Dec 2025 | |
| Logos Global Management LP |
13F
|
Company |
0.68%
|
1,375,000
|
$34,952,500 | — | 31 Dec 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.64%
|
1,296,008
|
$32,944,523 | — | 31 Dec 2025 | |
| Aberdeen Group plc |
13F
|
Company |
0.58%
|
1,184,122
|
$30,100,381 | — | 31 Dec 2025 | |
| Soleus Capital Management, L.P. |
13F
|
Company |
0.55%
|
1,110,000
|
$28,216,200 | — | 31 Dec 2025 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
|
Company |
0.44%
|
893,056
|
$22,703,000 | — | 31 Dec 2025 | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. |
13F
|
Company |
0.43%
|
863,000
|
$21,937,460 | — | 31 Dec 2025 | |
| GREAT POINT PARTNERS LLC |
13F
|
Company |
0.37%
|
750,000
|
$19,065,000 | — | 31 Dec 2025 | |
| UBS Group AG |
13F
|
Company |
0.36%
|
732,386
|
$18,617,252 | — | 31 Dec 2025 | |
| JENNISON ASSOCIATES LLC |
13F
|
Company |
0.35%
|
700,464
|
$17,805,795 | — | 31 Dec 2025 | |
| Peter Salzmann |
3/4/5
|
Chief Executive Officer, Director |
—
mixed-class rows
|
1,552,586
mixed-class rows
|
$17,543,264 | -$488,841 | 16 Apr 2025 | |
| S.c.a. Candriam |
13F
|
Individual |
0.34%
|
680,372
|
$17,295,793 | — | 31 Dec 2025 | |
| Frank Torti |
3/4/5
|
Director |
—
mixed-class rows
|
928,638
mixed-class rows
|
$16,667,378 | — | 01 Apr 2025 | |
| STEMPOINT CAPITAL LP |
13F
|
Company |
0.32%
|
644,959
|
$16,394,858 | — | 31 Dec 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.32%
|
642,974
|
$16,344,399 | — | 31 Dec 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.28%
|
566,148
|
$14,391,481 | — | 31 Dec 2025 | |
| Julia G. Butchko |
3/4/5
|
Chief Development Officer |
—
mixed-class rows
|
509,682
mixed-class rows
|
$14,251,795 | — | 21 Aug 2024 | |
| Connor, Clark & Lunn Investment Management Ltd. |
13F
|
Company |
0.23%
|
467,469
|
$11,883,062 | — | 31 Dec 2025 | |
| Pictet Asset Management Holding SA |
13F
|
Company |
0.19%
|
380,842
|
$9,681,004 | — | 31 Dec 2025 | |
| BNP PARIBAS FINANCIAL MARKETS |
13F
|
Company |
0.17%
|
353,056
|
$8,974,684 | — | 31 Dec 2025 | |
| Mark S. Levine |
3/4/5
|
Chief Legal Officer |
—
mixed-class rows
|
387,951
mixed-class rows
|
$8,124,353 | — | 20 Nov 2024 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.15%
|
313,481
|
$7,968,686 | — | 31 Dec 2025 | |
| William L. Macias |
3/4/5
|
Chief Medical Officer |
—
mixed-class rows
|
426,076
mixed-class rows
|
$7,454,384 | — | 19 Feb 2025 | |
| SUPERSTRING CAPITAL MANAGEMENT LP |
13F
|
Company |
0.14%
|
288,677
|
$7,338,169 | — | 31 Dec 2025 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.13%
|
259,117
|
$6,586,754 | — | 31 Dec 2025 | |
| Prosight Management, LP |
13F
|
Company |
0.12%
|
243,404
|
$6,187,330 | — | 31 Dec 2025 | |
| Trails Edge Capital Partners, LP |
13F
|
Company |
0.12%
|
240,165
|
$6,104,994 | — | 31 Dec 2025 | |
| Eva Renee Barnett |
3/4/5
|
Chief Financial Officer |
—
mixed-class rows
|
521,954
mixed-class rows
|
$5,907,965 | -$188,274 | 16 Apr 2025 | |
| BARCLAYS PLC |
13F
|
Company |
0.11%
|
232,326
|
$5,905,727 | — | 31 Dec 2025 | |
| Granahan Investment Management, LLC |
13F
|
Company |
0.11%
|
230,188
|
$5,851,379 | — | 31 Dec 2025 | |
| Nuveen, LLC |
13F
|
Company |
0.11%
|
226,489
|
$5,757,350 | — | 31 Dec 2025 | |
| TD ASSET MANAGEMENT INC |
13F
|
Company |
0.11%
|
224,960
|
$5,718,483 | — | 31 Dec 2025 |
Recent Insider Transactions by Companies or Individuals for Immunovant, Inc.
Showing up to 300 most recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Eric Venker | IMVT | Common Stock | Sale | -42.1% | $342,854 | $24.10 | -14,229 | 19,561 | 02 Apr 2026 | Direct |
| Eric Venker | IMVT | Common Stock | Disposed to Issuer | -90.8% | -334,960 | 33,790 | 01 Apr 2026 | Direct | ||
| Eric Venker | IMVT | Common Stock | Options Exercise | 368,750 | 368,750 | 01 Apr 2026 | Direct | |||
| Eric Venker | IMVT | Capped Value Appreciation Rights | Options Exercise | -25% | -368,750 | 1,106,250 | 01 Apr 2026 | Direct | ||
| Christopher van Tuyl | IMVT | Common Stock | Sale | -1.92% | $71,839 | $24.97 | -2,877 | 147,053 | 18 Mar 2026 | Direct |
| Melanie Gloria | IMVT | Common Stock | Sale | -1.87% | $90,184 | $27.85 | -3,238 | 170,273 | 25 Feb 2026 | Direct |
| Jay S. Stout | IMVT | Common Stock | Sale | -0.99% | $51,461 | $26.03 | -1,977 | 197,634 | 21 Jan 2026 | Direct |
| Jay S. Stout | IMVT | Common Stock | Sale | -0.6% | $31,914 | $26.53 | -1,203 | 199,611 | 07 Jan 2026 | Direct |
| Christopher van Tuyl | IMVT | Common Stock | Sale | -6.73% | $290,943 | $26.91 | -10,813 | 149,930 | 18 Dec 2025 | Direct |
| Roivant Sciences Ltd. | IMVT | Common Stock, $0.0001 par value per share | Purchase | 17.2% | $349,999,986 | $21.00 | 16,666,666 | 113,317,007 | 12 Dec 2025 | Direct |
| Andrew J. Fromkin | IMVT | Common Stock | Sale | -20.6% | $517,189 | $23.25 | -22,249 | 85,852 | 01 Dec 2025 | Direct |
| Douglas J. Hughes | IMVT | Common Stock | Sale | -11% | $348,665 | $23.24 | -15,000 | 120,773 | 01 Dec 2025 | Direct |
| Melanie Gloria | IMVT | Common Stock | Sale | -6.78% | $298,237 | $23.62 | -12,626 | 173,511 | 20 Nov 2025 | Direct |
| Michael Geffner | IMVT | Common Stock | Sale | -1.18% | $49,383 | $19.03 | -2,595 | 217,958 | 22 Oct 2025 | Direct |
| Jay S. Stout | IMVT | Common Stock | Sale | -1.24% | $47,956 | $19.03 | -2,520 | 200,814 | 22 Oct 2025 | Direct |
| Michael Geffner | IMVT | Common Stock | Sale | -0.57% | $20,734 | $16.30 | -1,272 | 220,553 | 08 Oct 2025 | Direct |
| Jay S. Stout | IMVT | Common Stock | Sale | -0.77% | $25,836 | $16.30 | -1,585 | 203,334 | 08 Oct 2025 | Direct |
| Eric Venker | IMVT | Capped Value Appreciation Rights | Award | 1,475,000 | 1,475,000 | 28 Jul 2025 | Direct | |||
| Eric Venker | IMVT | Stock Option (right to buy) | Award | 1,489,900 | 1,300,000 | 28 Jul 2025 | Direct | |||
| Jay S. Stout | IMVT | Common Stock | Sale | -1.35% | $50,911 | $18.15 | -2,805 | 204,919 | 23 Jul 2025 | Direct |
| Michael Geffner | IMVT | Common Stock | Sale | -1.06% | $43,288 | $18.15 | -2,385 | 221,825 | 23 Jul 2025 | Direct |
| Michael Geffner | IMVT | Common Stock | Sale | -0.51% | $19,998 | $17.24 | -1,160 | 224,210 | 09 Jul 2025 | Direct |
| Jay S. Stout | IMVT | Common Stock | Sale | -0.73% | $26,188 | $17.24 | -1,519 | 207,724 | 09 Jul 2025 | Direct |
| Tiago Girao | IMVT | Common Stock | Award | 208,388 | 208,388 | 01 May 2025 | Direct | |||
| Tiago Girao | IMVT | Stock Option (Right to Buy) | Award | 293,505 | 293,505 | 01 May 2025 | Direct | |||
| Jake Bauer | IMVT | Common Stock | Award | 25,016 | 25,016 | 01 May 2025 | Direct | |||
| Jake Bauer | IMVT | Stock Option (Right to Buy) | Award | 35,234 | 35,234 | 01 May 2025 | Direct | |||
| Robert Graham Susman | IMVT | Common Stock | Award | 25,016 | 25,016 | 01 May 2025 | Direct | |||
| Robert Graham Susman | IMVT | Stock Option (Right to Buy) | Award | 35,234 | 35,234 | 01 May 2025 | Direct | |||
| Jay S. Stout | IMVT | Common Stock | Sale | -0.91% | $28,471 | $14.79 | -1,925 | 209,243 | 23 Apr 2025 | Direct |
| Michael Geffner | IMVT | Common Stock | Sale | -1.03% | $34,742 | $14.79 | -2,349 | 225,370 | 23 Apr 2025 | Direct |
| Eva Renee Barnett | IMVT | Common Stock | Sale | -0.75% | $44,566 | $14.89 | -2,993 | 396,774 | 16 Apr 2025 | Direct |
| Peter Salzmann | IMVT | Common Stock | Sale | -0.7% | $123,900 | $14.89 | -8,321 | 1,178,191 | 16 Apr 2025 | Direct |
| Jay S. Stout | IMVT | Common Stock | Sale | -2.31% | $65,002 | $12.99 | -5,004 | 211,168 | 09 Apr 2025 | Direct |
| Michael Geffner | IMVT | Common Stock | Sale | -2.64% | $80,135 | $12.99 | -6,169 | 227,719 | 09 Apr 2025 | Direct |
| Eva Renee Barnett | IMVT | Common Stock | Sale | -2.69% | $143,708 | $12.99 | -11,063 | 399,767 | 09 Apr 2025 | Direct |
| Peter Salzmann | IMVT | Common Stock | Sale | -2.31% | $364,941 | $12.99 | -28,094 | 1,186,512 | 09 Apr 2025 | Direct |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.